Core Insights - Neurocrine Biosciences, Inc. is actively participating in investor conferences, with live webcasts available on their website [1] - The company focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio of FDA-approved products and a robust pipeline [2] Financial Performance - Neurocrine Biosciences reported its financial results for the third quarter ended September 30, 2025, indicating ongoing business activities and financial health [5] Upcoming Events - The company will have a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2025, and at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [5]

Core Insights - Neurocrine Biosciences, Inc. will participate in two investor conferences in May 2025, showcasing its commitment to engaging with investors and stakeholders [1][5]. Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [3]. - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, along with a robust pipeline of compounds in mid- to late-phase clinical development [3]. Upcoming Events - CEO Kyle Gano and VP of Investor Relations Todd Tushla will present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 11:20 AM Pacific Time in Las Vegas [5]. - CFO Matt Abernethy and CCO Eric Benevich will present at the RBCCM Global Healthcare Conference on May 20, 2025, at 11:30 AM Eastern Time in New York [5].